Truist Financial analyst Richard Newitter maintained a Buy rating on Boston Scientific (BSX – Research Report) today. The company’s shares closed last Friday at $67.13.
According to TipRanks, Newitter is a 5-star analyst with an average return of 17.2% and a 59.43% success rate. Newitter covers the Healthcare sector, focusing on stocks such as Nevro Corp, Inspire Medical Systems, and PROCEPT BioRobotics.
Currently, the analyst consensus on Boston Scientific is a Strong Buy with an average price target of $68.95, implying a 2.71% upside from current levels. In a report released on March 1, BTIG also reiterated a Buy rating on the stock with a $72.00 price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $67.40 and a one-year low of $46.20. Currently, Boston Scientific has an average volume of 6.43M.
Based on the recent corporate insider activity of 112 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BSX in relation to earlier this year. Last month, Edward Ludwig, a Director at BSX sold 7,000.00 shares for a total of $455,210.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Boston Scientific (BSX) Company Description:
Boston Scientific Corporation engages in the manufacturing of medical devices and products that are used in various interventional medical specialties worldwide. The company provides implantable devices including heart monitors, technologies for treating coronary artery disease and other cardiovascular disorders, and devices for diagnosing and treating gastrointestinal and pulmonary problems.
Read More on BSX:
- Boston Scientific receives FDA approval for Farapulse PFA System
- Wells upgrades Edwards Lifesciences, says tricuspid opportunity underappreciated
- Boston Scientific price target raised to $70 from $60 at Barclays
- Qualcomm downgraded, Cigna upgraded: Wall Street’s top analyst calls
- Boston Scientific price target raised to $63 from $55 at Deutsche Bank
